CGTLive’s Weekly Rewind – November 18, 2022


Review top news and interview highlights from the week ending November 18, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Leber Congenital Amaurosis CRISPR Therapy Paused for Disappointing Efficacy

Editas has paused enrollment in the BRILLIANCE trial after efficacy was only seen in a very small subset of patients.

2. Terese Hammond, MD, on Investigating iNKT Cells in COVID-Associated ARDS

The director of the CCU/ICU at Saint John’s Health Center discussed unmet respiratory treatment needs in the beginning of the COVID-19 pandemic.

3. CT-0508 Demonstrates Cytotoxicity in Solid Tumors

Updated data from a first-in-human trial were presented at the SITC 2022 meeting.

4. Amod Sarnaik, MD, on Lifileucel’s Place in the Treatment Lanscape for Advanced Melanoma

Sarnaik discussed the investigational TIL therapy’s potential as an additional option for patients.

5. Combination Adenovirus Therapy Shows Survival Gains in Newly Diagnosed High-Grade Glioma

CAN-2409 transduces tumor cells with the thymidine kinase gene, sensitizes these cells to valacyclovir, and stimulates patients’ immune response.

Recent Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment
Omid Hamid, MD, on Assessing TIL Combination Therapies, Expanding Past Melanoma
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
David Suhy, PhD, the cofounder and chief scientific officer of Earli
© 2024 MJH Life Sciences

All rights reserved.